Wednesday, June 25, 2025

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Related stories

Gurobi Unveils Gurobot an AI Assistant for Instant Support

Gurobi Optimization has introduced a new AI Assistant designed...

Deloitte Unveils AI tools to boost human-machine workforce

Designed to identify AI impacts on tasks and skills,...

EPAM unveil DIAL 3.0, evolved genAI platform for enterprise

EPAM Systems, a global digital engineering powerhouse, unveiled DIAL 3.0,...

HPE Launches NVIDIA AI Factory Solutions for Global Adoption

HPE and NVIDIA launch AI factory solutions to boost...

Kognitos Launches Neurosymbolic AI with $25M Series B

Kognitos, a leader in AI automation for business operations,...
spot_imgspot_img

Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging. The study describes the validation of Cleerly’s artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification

In two trials, the CREDENCE and PACIFIC-1 studies comprised a total of 513 patients who underwent coronary CT angiography, myocardial perfusion imaging with single photon emission CT (SPECT), and fractional flow reserve derived from CT (FFRCT).

Also Read: Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up. Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.

“This pivotal study was performed in two different international populations which shows that CCTA analyzed with the Cleerly AI-QCT ISCHEMIA device provides an accurate assessment of coronary ischemia,” said James P. Earls, MD, Chief Medical Officer of Cleerly. “These promising findings offer the possibility of a novel care paradigm for symptomatic coronary artery disease evaluation that performs comprehensive analysis of atherosclerosis, stenosis and ischemia from a single non-invasive CCTA test, which may offer the benefit of guiding clinical decision making for both coronary revascularization and medical therapy.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img